MYCOF - Psychedelic-Based Drugs Biotech Company Begins Trading On UK's AQSE Growth Market | Benzinga
Novel psychedelic-based drugs biotech Mydecine Innovations Group, Inc. (NEO:MYCO) (AQSE: MYIG) (OTC: MYCOF) (FSE: 0NFA) completed its admission to Access segment of the UK’s stock market, AQSE Growth Market. Trading started on Tuesday under ticker MYIG.
"We are incredibly excited to list our securities for trading in the UK on the AQSE Growth Market,” Josh Bartch, CEO of the company stated.” We believe Mydecine is at a pivotal phase in its development and look forward to increased exposure to UK and European investors alike.”
Mydecine is classified as a Healthcare company on the Access Segment of the Aquis Stock Exchange. It will have a dual listing with its common shares fully fungible through a CREST Depositary Interest (CDI). ...